Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LOSS OF DOPAMINE-D2 RECEPTOR-BINDING SITES IN PARKINSONIAN PLUS SYNDROMES
Autore:
HIERHOLZER J; CORDES M; VENZ S; SCHELOSKY L; HARISCH C; RICHTER W; KESKE U; HOSTEN N; MAURER J; POEWE W; FELIX R;
Indirizzi:
HUMBOLDT UNIV,STRAHLENKLIN CHARITE,CAMPUS VIRCHOW KLINIKUM,AUGUSTENBURGER PL 1 D-13353 BERLIN GERMANY HUMBOLDT UNIV,NUKL MED KLIN CHARITE D-13353 BERLIN GERMANY INNSBRUCK UNIV,NEUROL KLIN A-6020 INNSBRUCK AUSTRIA
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 6, volume: 39, anno: 1998,
pagine: 954 - 960
SICI:
0161-5505(1998)39:6<954:LODRSI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
C-11 RACLOPRIDE; DISEASE; IODINE-123-IBZM; DIAGNOSIS; DENSITY;
Keywords:
PARKINSONS DISEASE; PARKINSONIAN PLUS SYNDROMES; IODINE-123-IODOBENZAMIDE; SPECT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
J. Hierholzer et al., "LOSS OF DOPAMINE-D2 RECEPTOR-BINDING SITES IN PARKINSONIAN PLUS SYNDROMES", The Journal of nuclear medicine, 39(6), 1998, pp. 954-960

Abstract

This study analyzed temporal changes of striatal dopamine-D2 receptorbinding during the course of different extrapyramidal movement disorders using I-123-iodobenzamide (IBZM) SPECT. Methods: Eighteen patients(9 with Parkinson's disease, 9 with parkinsonian plus syndrome) were followed for 11-53 mo. Dopamine-D2 receptor binding was assessed usingI-123-IBZM SPECT at the beginning and at the end of the follow-up period. SPECT data were acquired 120 min postinjection of 3-5 mCi I-123-IBZM. A semiautomated algorithm was applied to the raw data for semiquantitative evaluation of regional cerebral receptor binding. Results: Intraobserver (r = 0.992) and interobserver (r = 0.930) variance was low for the semiautomated interpretation of the SPECT examination of thedopaminergic D2 receptor binding, reflecting a highly reproducible SPECT algorithm. Mean specific dopamine-D2 receptor binding was lower inpatients with parkinsonian plus syndrome compared to patients with Parkinson's disease on the initial (p < 0.001) as well as the follow-up study (p < 0.001). In patients with Parkinson's disease, we observed an unaffected receptor binding compared to a reduced binding of radiotracer in patients with parkinsonian plus syndrome during the course of the disease (p < 0.001). Conclusion: During the follow-up, patients with Parkinson's disease showed a constant dopamine-D2 receptor binding. In contrast, patients with parkinsonian plus syndrome revealed a decline of the binding of dopamine-D2 receptor. These findings are in agreement with histopathological data that demonstrated a preserved dopamine-M receptor status in patients with Parkinson's disease and a decline of the dopamine-M receptors in patients with parkinsonian plus syndrome. SPECT examinations using I-123-IBZM are useful for assessing dynamic changes of dopamine-D2 receptors in extrapyramidal movement disorders. Semiquantitative SPECT evaluations may provide valuable information for clinical management and prognosis of the patient with extrapyramidal movement disorders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 01:52:43